Enrollment in the Novartis study is now open to people between 12 and 21 years of age. With this clinical research trial, INNODIA evaluates whether the drug Iscalimab can slow the loss of β-cell function in young adult and children with new onset type 1 diabetes.
Approval to use Iscalimab in a lower age group
09. December 2021